论文部分内容阅读
由于缺乏非甲非乙型肝炎的诊断试剂,防碍了献血员的正确筛选,因此用大量按目前常规法筛选的混合血制备的凝血因子治疗血友病患者时,往往感染非甲非乙型肝炎的危险性极大,其感染率接近100%。1985年,Elstree采用血液制品实验室生产的经80℃、72小时干燥加热灭活病毒的凝血因子制剂治疗血友病患者,有明显降低非甲非乙型肝炎(NANBH)病毒感染的作用。本文作者比较了3组血友病病人接受经加热处理后的凝血因子治疗的结果。第1组19人,是以前未接受过治疗的血友病病人。无乙型肝炎感染指标,转氨酶正常,对乙型肝炎均有免疫力。第2组9人,曾接受过少量(少于
Due to the lack of non-A, non-B hepatitis diagnostic reagents, preventing the correct selection of blood donors, so with a large number of routine screening of mixed blood clotting factor preparation of hemophilia patients often infected with non-A non-B Hepatitis is extremely dangerous and its infection rate is close to 100%. In 1985, Elstree used a blood product laboratory to treat patients with hemophilia by heat-inactivated virus at 72 ° C for 72 hours at 80 ° C, significantly reducing non-A, non-B hepatitis virus (NANBH) infection. The authors compared the results of three hemophilia patients treated with heat-treated clotting factors. Group 1 of 19 people who were previously untreated hemophilia patients. No hepatitis B infection indicators, normal aminotransferase, hepatitis B are immune. Group 2 9 people, have received a small amount (less than